GenScript to Unveil New CRISPR Yeast Service at CRISPR Congress

Company to offer first CRISPR-based custom genome editing service for yeast strains

GenScript, the number one global provider of gene synthesis services, today announced it will unveil its custom gene editing services for the yeast, Saccharomyces cerevisiae, at the 2016 CRISPR Precision Gene Editing Congress. With this expansion of its CRISPR portfolio, GenScript becomes the only company to offer CRISPR services for yeast. ​

GenScript’s CRISPR Services Product Manager, Laura Geuss Ph.D., is scheduled to present details of the new service on Tuesday, February 23rd at 12:15 PM ET at the Hyatt Regency Boston. GenScript is an official 2016 CRISPR Congress sponsor.

"GenScript’s CRISPR services for yeast were developed to help researchers harness the power of yeast genome editing in the most efficient and effective ways possible. We are excited to discuss the applications of our CRISPR services with leading researchers in this quickly evolving, important field,” said Dr. Geuss. “Since S. cerevisiae is such a widely-used model organism, our CRISPR services are poised to help advance research on the utilization of yeast for the production of biofuels and chemicals, the study of human disease, and the development of novel therapeutics.”

Named the 2015 Breakthrough of the Year by the journal Science, the genome-editing technology CRISPR has impacted nearly every area of genetic research. The technology makes possible the editing of genomes with unprecedented precision, efficiency, and flexibility.

As one of the leading players in the genome editing market, GenScript began developing and offering CRISPR products and services for researchers in June 2013. In addition to its yeast gene editing services, the company’s portfolio of CRISPR-based services and products includes a gRNA design tool, gRNA constructs, genome-scale gRNA libraries, bacterial genome editing powered by a novel  λ Red-CRISPR/Cas9 system, and mammalian cell-line editing services.

For more information on GenScript’s CRISPR services portfolio, click here.

About GenScript – GenScript is the world leader in gene synthesis and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development, and synthetic biology. Since its founding in 2002, GenScript has provided services and products to scientists in more than 100 countries worldwide. The company delivers biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, in vitro and in vivo pharmacology and industrial synthetic biology products. For more information, visit


TWEET THIS: GenScript to Unveil New CRISPR-based custom genome editing service for yeast strains at @CrisprCongress #CRISPR16

Forward-Looking Statement Disclaimer: This press release contains forward-looking statements, including, without limitation, statements related to the earning and sales forecasts. These forward-looking statements are based upon GenScript’s current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: market condition, global stability, new technologies. The forward-looking statements made in this press release speak only as of the date of this press release. GenScript expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GenScript’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

For More Information Contact
Corporate Contact:
Sally Wang, Chief Operating Officer, GenScript
732.885.9188 ext 111

Media Contact:
Karl Schmieder